secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-122779
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx reports Q3 net loss of $72.7M; cash $234.4M; pipeline updates on AMX0035, avexitide, AMX0114
--------------------------------------------------------------------------------

- Net loss of $72.7M ($1.07 loss per share) vs net income of $20.9M in Q3 2023; acquired IPR&D expense of $36.2M for avexitide.
- Cash, cash equivalents and marketable securities of $234.4M as of Sept. 30, 2024, down from $309.8M at June 30, 2024; runway into 2026.
- Positive Phase 2 HELIOS data for AMX0035 in Wolfram syndrome: met primary endpoint (C-peptide improvement), with stabilization across secondary measures.
- Avexitide Phase 3 program in post-bariatric hypoglycemia on track to initiate in Q1 2025; topline data expected in 2026.
- FDA placed clinical hold on AMX0114 ALS trial, requesting lower starting dose; Amylyx plans to start LUMINA trial in Canada by end of 2024/early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000095017024122779/0000950170-24-122779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000095017024122779/amlx-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer